Accéder au contenu
Merck

NBS1-CtIP-mediated DNA end resection suppresses cGAS binding to micronuclei.

Nucleic acids research (2022-02-22)
Salim Abdisalaam, Shibani Mukherjee, Souparno Bhattacharya, Sharda Kumari, Debapriya Sinha, Janice Ortega, Guo-Min Li, Hesham A Sadek, Sunil Krishnan, Aroumougame Asaithamby
RÉSUMÉ

Cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS) is activated in cells with defective DNA damage repair and signaling (DDR) factors, but a direct role for DDR factors in regulating cGAS activation in response to micronuclear DNA is still poorly understood. Here, we provide novel evidence that Nijmegen breakage syndrome 1 (NBS1) protein, a well-studied DNA double-strand break (DSB) sensor-in coordination with Ataxia Telangiectasia Mutated (ATM), a protein kinase, and Carboxy-terminal binding protein 1 interacting protein (CtIP), a DNA end resection factor-functions as an upstream regulator that prevents cGAS from binding micronuclear DNA. When NBS1 binds to micronuclear DNA via its fork-head-associated domain, it recruits CtIP and ATM via its N- and C-terminal domains, respectively. Subsequently, ATM stabilizes NBS1's interaction with micronuclear DNA, and CtIP converts DSB ends into single-strand DNA ends; these two key events prevent cGAS from binding micronuclear DNA. Additionally, by using a cGAS tripartite system, we show that cells lacking NBS1 not only recruit cGAS to a major fraction of micronuclear DNA but also activate cGAS in response to these micronuclear DNA. Collectively, our results underscore how NBS1 and its binding partners prevent cGAS from binding micronuclear DNA, in addition to their classical functions in DDR signaling.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Hydroxyurée, 98%, powder
Sigma-Aldrich
Aphidicolin, Aphidicolin, CAS 38966-21-1, is a cell-permeable antibiotic that acts as a cell synchronization agent. Blocks the cell cycle at early S-phase.
Millipore
Protease Inhibitor Cocktail Set VI, The Protease Inhibitor Cocktail Set VI controls the activity of Protease. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.